The worry had been that the Alzheimer's conference would have blockbuster news on a cure or major disease-modifying results from these big players. Now that we know the news is .... meh.... that's good for ACAD and it's ongoing trials for symptom relief. We may chop around here in the high 40's low 50's, but they're still a prime company to receive an offer - still a tiny company with a can't miss drug about ready to launch.
I agree. I can only wonder that perhaps there's interest on the part of the institutions to keep prices low as they can until they can hit they buy program. Makes no sense it's sitting at 34. Yahoo finance says 80% owned by institutions. Don't give away your shares on the fall from 35.1 to 33.9 in AH. Nothing in the CC justifies anything but further gains.
Much better play is CRUS, which is at PEG of 0.63, fwd PE of only 12, and just beat revs by 25%, beat similar on fwd Q2 revs, Beat on earnings, and already had sold off on AAPL fall. It's a value AND growth play. Risk/reward says buy
so? That just meets - why the hell is the stock up 10% or more? I suppose the selloff a month ago anticipating another horrendous quarter. Tough to buy into a short-covering panic by individual investors in the thin AH Pass. Good luck you guys.
I did something I rarely do - I payed up in AH for this stock, which has been whacked by the AAPL "disappointment"; artificial, as AAPL had a good quarter, just not as spectacular as momo's had hoped. This can easily get back to 38 before hitting overhead resistance. Revs beat, Rev projections beat, Earnings beat, and AAPL rising again in AH as well. Buy more, now that it dipped back to the low 34's for a moment.
why pay off debt when int rates so low? Buyback makes more sense. 8% of shares short, and it's only gotten back to the levels where some overhead resistance exists dating back a month. The separation of the equipment rental business is a bigger deal, though. That'll attract a much higher multiple, and they'll retain owership of shares. The risk/reward here is very good, even at 20.
I don't see anywhere in the announcement how many were in the study. 27% pos vs 23% positive in control doesn't sound impressive to me, unless there's a thousand in the study. Did they start with a tiny cohort just so they could hope for some barely marginal lucky fluke in the right direction? Who knows how many patients were in this study?
This stock is up only 25%, when the BEAT was 3 times that, and the plan is clearly working... What am I not seeing? This makes no sense. This stock should be up at 3 at least. Is it just weekend rebalancing nonsense from the smallcaps? I'm trying to find understanding but the only other theory is just profit taking by some who were in at 1.0, mindless profit taking with no notice of the new fundamentals.
I"m not a short either. I just wanted some rationale for $2/pill. What's the great advantage over aspirin or ibuprofen. I'm pondering investing on the pullback.
Short interest only 1% of float. Doesn't sound like the typical fly-by-night outfit that the shorts love. The announcement this morning says AXN will be the sole distributor of Tilidine HCL in China. There's a lot of pain in China to be treated.
It's clear what's happened - the actual news already came out, at 3am this morning, the China license deal. This news conference was just to make a formal announcement. Note the wording in the 3am announcement, shown on the ThinkorSwim news feed for example. "culmination of 12 years of work" etc. Very similar to the news conference, which seems to either be going late, or some other snafu. Anyway, I see no reason to sell.
Except Monday, we've had a painful rally (for the shorts) every opening. So I have just one question for the shorts, as we head into the close.... do you feel lucky? Well do ya...punks!! I'll hold long and sell to you on a good strong spike.
I don't know why the stock shouldn't be bouncing well off 2 and heading north. They only paid 10% of their float for Anaconda. And they sold off 10% and a little more, this past month. The stock is selling below book. Yes, there's no immediate catalyst on drug candidates, but any good news should rocket this stock. It's a low risk/high return bet.
I see bursts of short-covering on my ticker.... The ER was darn good, so I expect the trickle to get larger as the day goes on.